Streptococcus Vaccine Offers Hope for Tilapia Sector

Hopes for the development of an effective vaccine to protect tilapia from Streptococcus have been given a boost following the publication of the results of a new study.

Streptococcus agalactiae is one of the most widespread bacterial pathogens impacting the international tilapia farming sector, causing great losses of intensive tilapia farming – with the value of losses incurred in China (the world’s largest producer of the species) estimated at up to $1.5 billion a year. 

Outbreaks of the disease are generally dealt with through the use of antibiotics, but a vaccine is seen as a preferable method for numerous reasons – not least due to fears of the spread of antibiotic resistance and because it leads to an imbalance of bacterial microbiota both within the fish and their habitat. The results of the study, led by researchers from the School of Life Sciences at Sun Yat‐Sen University, have been published in the latest issue of the Journal of Fish Diseases.

In order to develop a potential live attenuated vaccine, the researchers developed a re‐attenuated S. agalactiae (named TFJ‐ery) from a natural low‐virulence S. agalactiae strain TFJ0901 through selection of resistance to erythromycin.

When Nile tilapia were intraperitoneally injected with TFJ‐ery, the mortality of fish was decreased, while the RPS of fish immunized with TFJ‐ery at a dose of 5.0 × 107CFU was 95.00%, 93.02% and 100.00% at 4, 8 and 16 weeks post‐vaccination, respectively. ELISA results showed that the vaccinated fish produced significantly higher (p